CompletedNot Applicable

Initial Clinical and CBCT Outcomes of Enamel Matrix Derivative-Based Regenerative Therapy in Vertical Bone Defects

Bulgaria48 participantsStarted 2022-06-24

Plain-language summary

Study of the effectiveness of the application of regenerative therapy with autogenous, platelet-rich plasma in vertical defects Investigation of the effectiveness of the application of regenerative therapy with enamel matrix derivatives in vertical bone defects Study of the effectiveness of the application of guided tissue regeneration in vertical bone defects with Barrier membrane and Barrier membrane and autogenous platelet-rich plasma

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * good oral hygiene * written informed consent * age * no systemic diseases Exclusion Criteria: * smokers * horizontal bone loss * untreated periodontium disease

What they're measuring

Probing depth in mm

Timeframe: 6 months

Level of Margo Gingivalis in mm

Timeframe: 6 months

Clinical attachment level in mm

Timeframe: 6 months

The distance from the ECJ to the base of the bone defect in mm

Timeframe: 6 months

The distance from the ECJ to the apex of the bone defect in mm

Timeframe: 6 months

The width of the bone defect in mm

Timeframe: 6 months

Trial details

NCT IDNCT06639555

SponsorTsvetalina Gerova-Vatsova

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-15

View on ClinicalTrials.gov More Vertical Alveolar Bone Loss trials